Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caplin Point Laboratories reported consolidated revenue from operations of ₹534 Cr in Q2 FY26, up 10.5% YoY, with H1 FY26 total revenue at ₹1,098 Cr, up 11.9% YoY. Consolidated PAT grew 22.5% YoY in Q2 to ₹160.2 Cr and 21.6% YoY in H1 to ₹311 Cr. EBITDA margin expanded to 38.9% in Q2 (from 36.8%) and 38.3% in H1 (from 36.3%), driven by new product launches. The US market grew strongly at 27% YoY to ₹221 Cr in H1. Free cash reserves stand at ₹1,334 Cr and total liquid assets at ₹2,358 Cr. On the standalone basis, however, revenue from operations declined to ₹175.18 Cr in Q2 (from ₹201.93 Cr) and ₹357.75 Cr in H1 (from ₹393.57 Cr). The Board appointed Mr. Ashok Partheeban and Mr. Vivek Partheeban as Vice-Chairmen and Dr. K C John as Independent Director.
Strong consolidated profit growth and margin expansion, backed by a net cash-positive balance sheet, are positive for shareholders. However, declining standalone revenue and dividend dependence on subsidiaries may concern some investors; overall the result is a healthy operational performance.